Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will present data on Friday, Jan. 22, 2016, from its ongoing phase 2 PANOVA clinical trial at the American Society of Clinical Oncology 2016 …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, will provide a business update as well as its preliminary operating statistics for the fourth quarter and full year 2015 at the 34th Annual J.P. Morgan Healthcare Conference. The fourth quarter of 2015 was marked by substantial …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it submitted a premarket approval (PMA) partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Optune, a Tumor Treating Fields (TTFields) therapy delivery device, in patients with newly diagnosed glioblastoma. The Japanese Ministry of Health, Labour and Welfare (MHLW) …

Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) filed a premarket approval (PMA) supplement application for its new, second generation Optune system with the U.S. Food and Drug Administration on Dec. 22, 2015. FDA approval of …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate in the 34th Annual J.P. Morgan Healthcare Conference on Jan. 13, 2016, in San Francisco. Bill Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation will begin at 9:30 a.m. PST and will be followed by a …